<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2808234062
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2006
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        STALEVO 50-12.5-200MG FILM COATED TAB.
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ENTACAPONE,LEVODOPA,CARBIDOPA
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        200,50,12.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        107.10
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ORION PHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ORION PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Exeltis Healthcare S.L 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N04BA03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Stalevo contains three active substances in one film-coated tablet. Each tablet contains levodopa, used to treat Parkinson&rsquo;s disease. The two other active substances: carbidopa and entacapone improve the antiparkinson effects of levodopa.</p><p>Stalevo 50/12.5/200 mg tablets: brownish- to greyish-red, round, convex tablets marked with &lsquo;LCE 50&rsquo; on one side.</p><p>Stalevo 100/25/200 mg: brownish- to greyish-red, oval tablets marked with &lsquo;LCE 100&rsquo; on one side.</p><p>Stalevo 150/37.5/200 mg: brownish- to greyish-red, elongated-ellipse shaped tablets marked with &lsquo;LCE 150&rsquo; on one side.</p><p>Stalevo 200/50/200 mg: dark brownish red, oval-shaped tablets marked with &lsquo;LCE 200&rsquo; on one side.</p><p>Your doctor has prescribed Stalevo to treat your Parkinson&#39;s disease.</p><p>Parkinson&#39;s disease is a disorder of the nervous system. It is caused by a lack of dopamine, a natural substance that is produced in the brain. Dopamine relays messages in the part of the brain that controls muscle movement. When too little dopamine is produced, problems with movement result.</p><p>Levodopa works by increasing the level of dopamine in the brain.</p><p>Stalevo helps in relieving the symptoms of Parkinson&rsquo;s disease, such as shaking of the limbs, and stiffness and slowness of movement, which make it difficult to perform normal daily activities.</p><p>You may also be given other medicines to help treat this condition.</p><p>Ask your doctor if you have any questions about how this medicine works or why this medicine has been prescribed for you.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>a.&nbsp;&nbsp;&nbsp; Do not take Stalevo:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you are allergic</strong> (hypersensitive) to levodopa, carbidopa or entacapone or any of the other ingredients of Stalevo.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have a severe liver impairment.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have narrow-angle glaucoma</strong> (an eye disorder).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have a tumour of the adrenal gland </strong>(known as pheochromocytoma; this may increase the risk of severe high blood pressure)<strong>.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you are taking certain medicines to treat depression</strong> (selective MAO-A plus MAO-B inhibitors, or non- selective MAO-inhibitors).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have ever had neuroleptic malignant syndrome</strong> (NMS; this is a rare reaction to medicines used to treat severe mental disorders).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have ever had non-traumatic rhabdomyolysis</strong> (a rare muscle disorder).</p><p>If any of these applies to you, talk to your doctor before taking Stalevo.</p><p>b.&nbsp;&nbsp; Take special care with Stalevo</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have ever had a heart attack, asthma or any other diseases of the heart, blood vessels or lungs.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a liver problem.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a severe renal problem.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have ever had kidney, liver or hormone-related diseases.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have ever had inflammatory bowel disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have ever had stomach ulcers.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have ever had convulsions.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have ever suffered from any form of severe mental disorder.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you feel depressed, have suicidal thoughts, or notice unusual changes in your behaviour.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have chronic wide-angle glaucoma. Your dose may need to be adjusted and the pressure in your eyes may need to be monitored.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking other medicines that can cause low blood pressure. You should be aware that Stalevo may make these reactions worse.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If uncontrolled movements begin or get worse after you start taking Stalevo, your doctor may need to change the dose of your antiparkinson medications.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor if you or your family/carer notices you are developing addiction-like symptoms leading to craving for large doses of Stalevo and other medicines used to treat Parkinson&rsquo;s disease (known as dopamine dysregulation syndrome).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor if you or your family/caregiver notices you are developing urges or cravings to behave in ways that are unusual for you or you cannot resist the impulse, drive or temptation to carry out certain activities that could harm yourself or others. These behaviours are called impulse control disorders and can include addictive gambling, excessive eating or spending, an abnormally high sex drive or a preoccupation with an increase in sexual thoughts or feelings. Your doctor may need to review your treatments.</p><p>If any of the above applies to you, <strong>contact your doctor</strong>.<strong> </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you find yourself suddenly falling asleep,</strong> or if you feel very drowsy (see also the section &#39;Driving and using machines&#39;).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If your muscles get very rigid or jerk violently, or if you suffer from tremors, agitation, confusion, fever, rapid pulse, or wide fluctuations in your blood pressure </strong>(signs of Neuroleptic Malignant Syndrome, NMS).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you experience diarrhea,</strong> your doctor may follow-up on your weight in order to prevent potential excessive weight loss<strong>.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you experience progressive anorexia, asthenia (weakness, exhaustion) and weight decrease within a relatively short period of time, contact your doctor. He/she may decide to conduct a general medical evaluation including liver function.</p><p>If any of these occurs, <strong>tell your doctor immediately.</strong></p><p>If you are going to have a surgery with a general anaesthesia, inform the doctor that you are taking Stalevo.</p><p><strong>If you feel the need to stop using Stalevo, please consult your doctor first.</strong> It may be necessary to reduce the dose of Stalevo gradually, and make changes in your other antiparkinson medication, in order to prevent side effects and keep your Parkinson&rsquo;s symptoms from getting worse.</p><p>Older people</p><p>If you are over 65, you can take Stalevo without dose adjustment.</p><p>Children and adolescents</p><p>The use of Stalevo has not been established in children and adolescents less than 18 years of age and can therefore not be recommended.</p><p>&nbsp;</p><p>c. Taking other medicines, herbal or dietary supplements</p><p><strong>Tell your doctor or pharmacist </strong>if you are taking or have recently taken any other medicines, including any to lower your blood-pressure, non-prescription medicines or herbal products.</p><p>Stalevo may increase the effects and side effects of certain antidepressants and some other medicines. These include MAO-A inhibitors (e.g. moclobemide), tricyclic antidepressants (e.g. amitryptiline) and noradrenaline reuptake inhibitors (e.g. desipramine, maprotiline and venlafaxine), as well as paroxetine, rimiterole, isoprenaline, adrenaline, noradrenaline, dopamine, dobutamine, alpha-methyldopa and apomorphine.</p><p>Watch out for additional effects if you take these medicines while being treated with Stalevo.</p><p>The effects of Stalevo may be weakened by certain medicines. It includes medicines:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; used to treat mental disorders (dopamine antagonists),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; used to treat nausea and vomiting (dopamine antagonists),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; used to prevent convulsions (phenytoin),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; used to relax the muscles (papaverine).</p><p>Tell your doctor if you are taking these medicines, or if you notice that Stalevo does not work as well when you take them.</p><p>Stalevo may make it harder for you to digest iron. Therefore, do not take Stalevo and iron supplements at the same time. After taking one of them, wait at least 2 to 3 hours before taking the other.</p><p>&nbsp;</p><p>d. Pregnancy, breast‑feeding and fertility</p><p>If you are pregnant or think you may be pregnant,<strong> </strong>do not take Stalevo before consulting your doctor. Stalevo is not to be used during pregnancy unless clearly necessary. Your doctor will discuss with you the potential risk of taking Stalevo during pregnancy.</p><p>Breast-feeding mothers</p><p>If you are breast-feeding, tell your doctor. You should not breast-feed while under treatment with Stalevo.</p><p>e. Driving and using machines</p><p>Stalevo may lower your blood pressure, which may make you feel light-headed or dizzy. Therefore, be particularly careful when you drive or when you operate any tools or machines.</p><p>If you feel very drowsy, or if you sometimes find yourself suddenly falling asleep, you must not drive or do anything else that requires you to be alert (operate tools or machines). Consult your doctor for advice. Otherwise, you may put yourself and others at risk of serious injury or death.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Stalevo exactly as your doctor has instructed you to. You should check with your doctor or pharmacist if you are unsure.</p><p>How much to take</p><p>Each Stalevo tablet contains one complete dose of levodopa, carbidopa and entacapone. Each time you take Stalevo, take only one tablet. The tablet is not intended to be split or broken into smaller pieces.</p><p>Your doctor will tell you exactly how many tablets of Stalevo to take each day. Depending on how you respond to treatment, your doctor may suggest a higher or lower dose.</p><p>Stalevo 50/12.5/200 mg, 75/18.75/200 mg, 100/25/200 mg, 125/31.25/200 mg and 150/37.5/200 mg: Do not take more than 10 tablets a day.</p><p>Stalevo 175/43.75/200 mg: Do not take more than 8 tablets per day.</p><p>Stalevo 200/50/200 mg: Do not take more than 7 tablets per day.</p><p>Talk to your doctor or pharmacist if you think the effect of Stalevo is too strong or too weak, or if you detect possible side effects.</p><p>When and how to take Stalevo</p><p>Strictly follow your doctor&rsquo;s instructions on when and how to use Stalevo, other levodopa medications and other antiparkinson drugs. Check with your doctor or pharmacist if you are unsure about these instructions or the text printed on the packaging.</p><p>Taking Stalevo with food and drink</p><p>Stalevo may be taken with or without food.</p><p>For some patients, Stalevo may not be well absorbed if it is taken with, or shortly after eating protein-rich food (such as meats, fish, dairy products, seeds and nuts). Consult your doctor if you think this applies to you.</p><p>Do not take Stalevo and iron supplements at the same time. After taking one of them, wait at least 2 to 3 hours before taking the other.</p><p>a.&nbsp;&nbsp;&nbsp; If you take more Stalevo than you should</p><p>If you have accidentally taken too many Stalevo tablets, <strong>talk to your doctor immediately. </strong>You may require medical attention.</p><p>&nbsp;</p><p>b.&nbsp;&nbsp; If you forget to take Stalevo</p><p>If there is more than an hour until your next dose: take one tablet now, and the next tablet at the normal time.</p><p>If there is less than an hour until your next dose: take a tablet now, wait an hour, then take another tablet. After that go back to your normal schedule.</p><p>Do not take a double dose to make up for forgotten doses. Always leave at least an hour between Stalevo tablets, to avoid possible side effects.</p><p>If you are unsure about what to do, consult your doctor.</p><p>c.&nbsp;&nbsp;&nbsp; If you stop taking Stalevo</p><p>Do not stop taking Stalevo unless your doctor tells you to. In such case, your doctor may need to re-adjust the dosage of your other antiparkinson medications, especially levodopa, to give sufficient control of your symptoms. Abrupt discontinuation of both Stalevo and other antiparkinsonian medication may result in unwanted side effects, such as severe muscular stiffness, high fever and altered consciousness.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>As with all medicines, patients treated with Stalevo may experience side effects, although not everybody gets them. If you experience any of these side effects, talk to your doctor as soon as you can. Many of the side effects can be relieved by adjusting the dose.</p><p>If during the treatment with Stalevo you experience the following symptoms, <strong>contact your doctor immediately:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your muscles get very rigid or jerk violently, you get tremors, agitation, confusion, fever, rapid pulse, or wide fluctuations in your blood pressure. These can be symptoms of neuroleptic malignant syndrome (NMS, a rare severe reaction to medicines used to treat disorders of the central nervous system) or rhabdomyolysis (a rare severe muscle disorder).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reaction, the signs may include hives (nettle rash), itching, rash, swelling of your face, lips, tongue or throat. This may cause difficulties in breathing or swallowing</p><p>If you notice any other possible side effects not mentioned in this leaflet, please inform your doctor or pharmacist</p><p>Very common (<em>affecting more than 1 user in 10</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uncontrolled movements (dyskinesias);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; harmless reddish-brown discolouration of the urine;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle pain;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea.</p><p>Common (<em>affecting 1 to 10 users in 100</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart or artery disease events other than a heart attack (e.g. chest pain); irregular heart rate or rhythm;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; light-headedness or fainting due to low blood pressure; high blood pressure;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; worsening of Parkinson&rsquo;s symptoms;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness; drowsiness;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting; abdominal pain and discomfort; heartburn; dry mouth; constipation;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inability to sleep; hallucinations; confusion; abnormal dreams, including nightmares; mental changes, including problems with memory or thinking; anxiety and depression (possibly with thoughts of suicide); tiredness; chest pain;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; more frequent falling; impaired walking; loss of both strength and energy;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased sweating; rashes;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle cramps; involuntary muscle contractions; swelling of legs;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred vision;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anaemia; decreased appetite; decrease weight;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache; joint pain;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; urinary tract infection.</p><p>Uncommon (<em>affecting 1 to 10 users in 1,000</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart attack;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding in the gut;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal liver function tests; psychotic symptoms; feeling agitated;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the colon (colitis);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin, nail, hair and sweat discolourations;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in the blood cell count which may result in bleeding;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swallowing difficulties;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inability to urinate.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; generally feeling unwell</p><p>Some side effects can be rare or very rare</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; convulsions</p><p>Other</p><p>The exact frequencies of these side effects are not known but are based upon reports received since the product has been on the market:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hepatitis (inflammation of the liver);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; excessive daytime somnolence; sudden sleep onset episodes;</p><p>You may experience the following side effects:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Craving for large doses of Stalevo in excess of that required to control motor symptoms, known as dopamine dysregulation syndrome. Some patients experience severe uncontrolled movements (dyskinesias), mood swings, or other side effects after taking large doses of Stalevo.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inability to resist the impulse to perform an action that could be harmful, which may include:</p><p>- strong impulse to gamble excessively despite serious or personal family consequences,</p><p>- altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive,</p><p>- uncontrollable excessive shopping or spending,</p><p>- binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger).</p><p>Tell your doctor if you experience any of these behaviors; your doctor will discuss ways of managing or reducing the symptoms.</p><p><strong>If any of the side effects get serious, tell your doctor, nurse or pharmacist.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There are no special storage conditions.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use after the expiry date printed on the pack.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use if the pack is damaged or shows signs of tampering.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the reach and sight of children.</p><p>Do not store above 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Stalevo 50/12.5/200 mg, 100/25/200 mg, 150/37.5/200 mg, 200/50/200 mg film-coated tablets</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The <strong>active substances </strong>of Stalevo are levodopa, carbidopa and entacapone.</p><p>The <strong>other ingredients </strong>are croscarmellose sodium, magnesium stearate, maize starch, mannitol, povidone, glycerol 85%, hypromellose, polysorbate 80, red iron oxide (E 172), sucrose, titanium dioxide (E 171), yellow iron oxide (E 172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Stalevo contains three active substances in one film-coated tablet. Each tablet contains levodopa, used to treat Parkinson’s disease. The two other active substances: carbidopa and entacapone improve the antiparkinson effects of levodopa.
Stalevo is available in four different dosage strengths: 50/12.5/200 mg, 100/25/200 mg, 150/37.5/200 mg and 200/50/200 mg film-coated tablets and comes in pack size 30 tablets 
Stalevo tablets have a thin brownish- to greyish-red coating over an orange to yellow core.
Stalevo 50/12.5/200 mg tablets: brownish- to greyish-red, round, convex tablets marked with ‘LCE 50’ on one side.
Stalevo 100/25/200 mg: brownish- to greyish-red, oval tablets marked with ‘LCE 100’ on one side.
Stalevo 150/37.5/200 mg: brownish- to greyish-red, elongated-ellipse shaped tablets marked with ‘LCE 150’ on one side.
Stalevo 200/50/200 mg: dark brownish red, oval-shaped tablets marked with ‘LCE 200’ on one side. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorization Holder for this Product is Novartis Pharma.</p><p>www.Novartis.com</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved by Novartis Pharmaceutical Company in 05/2019.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي عقار ستاليفو على ثلاث مواد فعالة في قرص مغلف واحد. كل قرص يحتوي على ليفودوبا، وهي مادة تستخدم لعلاج مرض الشلل الرعَّاش (مرض باركنسون). <em>المادتان الفعالتان الأخرتان هما</em><em>:</em> كاربيدوبا وإنتاكابون وهما مادتان تحسنان تأثيرات ليفودوبا المضادة لمرض الشلل الرعاش (مرض باركنسون).</p><p>عقار ستاليفو أقراص 50/12.5/200 مجم: أقراص ذات لون أحمر بني مائل إلى الرمادي، مستديرة الشكل، محدبة، على أحد جانبيها العلامة &quot;LCE 50&quot;.</p><p>عقار ستاليفو 100/25/200 مجم: أقراص ذات لون أحمر بني مائل إلى الرمادي، بيضاوية الشكل، على أحد جانبيها العلامة &quot;LCE 100&quot;.</p><p>عقار ستاليفو 150/37.5/200 مجم: أقراص ذات لون أحمر بني مائل إلى الرمادي، ذات شكل بيضاوي مستطيل، على أحد جانبيها العلامة &quot;LCE 150&quot;.</p><p>عقار ستاليفو 200/50/200 مجم: أقراص ذات لون أحمر داكن يميل إلى البني، بيضاوية الشكل، على أحد جانبيها العلامة &quot;LCE 200&quot;.</p><p>قد وصف لك طبيبك عقار ستاليفو لعلاج مرض الشلل الرعَّاش (مرض باركنسون) الذي تعاني منه.</p><p>يُعد مرض الشلل الرعَّاش (مرض باركنسون) اضطرابًا بالجهاز العصبي. يحدث هذا المرض بسبب نقص الدُّوبامِين، وهو مادة طبيعية تنتج في المخ. يقوم الدُّوبامِين بنقل الرسائل في جزء المخ الذي يتحكم في حركة العضلات. عندما يكون إنتاج الدُّوبامِين ضئيلًا جدًّا، فتحدث مشاكل في الحركة.</p><p>يعمل ليفودوبا عن طريق زيادة مستوى الدُّوبامِين في المخ.</p><p>يُساعد عقار ستاليفو على تخفيف أعراض مرض الشلل الرعَّاش (مرض باركنسون)، مثل رعشة الأطراف والتيبس وبطء الحركة، مما يجعل من الصعب أداء الأنشطة اليومية العادية.</p><p>قد يتم إعطاؤك أيضًا أدوية أخرى للمساعدة على علاج هذه الحالة المرضية.</p><p>استشر طبيبك إذا كانت لديك أية أسئلة حول كيفية عمل هذا الدَّواء أو لماذا تم وصف هذا الدَّواء لك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>موانع تناول عقار ستاليفو:</p><p><strong>إذا كنت تعاني من حساسية</strong> (حساسية مفرطة) تجاه ليفودوبا, أو كاربيدوبا أو إنتاكابون أو أيٍّ من مكونات عقار ستاليفو الأخرى.</p><p><strong>إذا كنت تُعاني من قصور كبدي شديد</strong><strong>.</strong></p><p><strong>إذا كان لديك زرق ضيِّق الزاوية</strong> (أحد اضطرابات العين).</p><p><strong>إذا كنت مصابًا بورم في الغدة الكظرية </strong>(يُعرف باسم ورم القواتم، قد يزيد ذلك من خطر الإصابة بارتفاع شديد بضغط الدَّم).</p><p><strong>إذا كنت تتناول أدوية معينة لعلاج الاكتئاب</strong> (مثبطات أوكسيديز أحادي الأمين - أ الانتقائية بالإضافة إلى مثبطات أوكسيديز أحادي الأمين - ب، أو مثبطات أوكسيديز أحادي الأمين غير الانتقائية).</p><p><strong>إذا كنت قد عانيت من قبل من المُتَلَازِمَة الخَبيثَة للدَّواءِ المُضادِّ للذُّهان</strong> (وهي تفاعل نادر تجاه الأدوية التي تستخدم لعلاج الاضطرابات النفسية الشديدة).</p><p><strong>إذا كنت قد عانيت من قبل من انحلال الربيدات غير الرضحي</strong> (وهو اضطراب عضلي نادر).</p><p>إذا انطبق عليك أي مما سبق، فتحدَّث إلى طبيبك قبل تناول عقار ستاليفو.</p><p>الاحتياطات الخاصة عند استخدام عقار ستاليفو</p><p>إذا كنت قد عانيت من قبل من نوبة قلبية أو ربو أو أي أمراض أخرى بالقلب أو الأوعية الدَّموية أو الرئتين.</p><p>إذا كنت تُعاني من مشكلة بالكبد.</p><p>إذا كنت تُعاني من مشكلة كلوية شديدة.</p><p>إذا كنت قد عانيت من قبل من أمراض بالكلى أو الكبد أو أمراض مرتبطة بالهرمونات.</p><p>إذا كنت قد عانيت من قبل من مرض التهاب الأمعاء.</p><p>إذا كنت قد عانيت من قبل من قرح بالمعدة.</p><p>إذا كنت قد عانيت من قبل من تشنجات.</p><p>إذا كنت قد عانيت من قبل من أي شكل من أشكال الاضطرابات النفسية الشديدة.</p><p>إذا كنت تشعر باكتئاب أو تراودك أفكار انتحارية أو تلاحظ حدوث تغيرات غير معتادة في سلوكك.</p><p>إذا كنت تعاني من الزَّرق المزمن واسع الزاوية. قد يستلزم الأمر تعديل جرعتك ومراقبة الضغط داخل عينيك.</p><p>إذا كنت تتناول أدوية أخرى قد تُؤدي إلى انخفاض ضغط الدَّم. يجب أن تكون على دراية بأن عقار ستاليفو قد يفاقم من حدوث هذه التفاعلات.</p><p>إذا بدأت الحركات غير المتحكم بها في الحدوث أو تفاقمت بعدما بدأت في تناول عقار ستاليفو، فقد يحتاج طبيبك لتغيير جرعة الأدوية المضادة لمرض الشلل الرعاش (مرض باركنسون) الخاصة بك.</p><p>إذا كان طبيبك قد أخبرك بأنك لا تتحمل بعض أنواع السكريات، فاتصل به قبل تناوُل هذا المنتج الدَّوائي.</p><p>أخبر طبيبك إذا لاحظت أنت أو أسرتك/ مقدم الرعاية أنك تعاني من أعراض تشبه أعراض الإدمان وتجعلك ترغب في تناول جرعات كبيرة من عقار ستاليفو والأدوية الأخرى المستخدمة لعلاج مرض الشلل الرعَّاش (مرض باركنسون) (وهي ما تسمى بمتلازمة خلل تنظيم الدوبامين).</p><p>أخبر طبيبك إذا لاحظت أنت أو أسرتك/ مقدم الرعاية تطور الدوافع أو الرَّغبة الشديدة للتَّصرف بطرق غير معتادة بالنسبة لك أو أنك لا تستطيع مقاومة الاندفاع أو الرغبة أو الإغراء؛ للقيام ببعض الأنشطة التي قد تضر بك أو تضر بالآخرين. هذه السلوكيات تُسمى باضطرابات التَّحكم في الاندفاع ويمكن أن تشمل: إدمان القمار أو الأكل أو الإنفاق بنهم أو ازدياد الرغبة الجنسية بشكل غير طبيعي أو الانشغال بازدياد الأفكار أو المشاعر الجنسية. قد يحتاج طبيبك إلى مراجعة العلاجات الخاصة بك.</p><p>إذا كان أيٌّ مما سبق ينطبق عليك، <strong>فاتصل بطبيبك</strong>.<strong> </strong></p><p><strong>إذا وجدت نفسك غلبك النوم فجأة،</strong> أو شعرت بنعاس شديد (انظر أيضًا قسم: &quot;القيادة واستخدام الآلات&quot;).</p><p><strong>إذا تصلبت عضلاتك بشدة أو كانت ترتعش بشدة، أو إذا عانيت من ارتعاش عضلي أو هياج أو ارتباك أو حمى أو تسارع النبض، أو من تذبذبات كبيرة في ضغط الدَّم لديك </strong><strong>(</strong>علامات على الإصابة بالمُتَلَازِمَة الخَبيثَة للدَّواءِ المُضادِّ للذُّهان).</p><p><strong>إذا عانيت من إسهال</strong>، فقد يتابع طبيبك وزنك لمنع الفقدان الزائد والمحتمل في الوزن.</p><p>إذا عانيت من فقدان شهية مترقٍّ ووهن (ضعف، إنهاك) وانخفاض في الوزن خلال فترة زمنية قصيرة نسبيًّا، فاتصل بطبيبك/ طبيبتك. قد يقرر/ تقرر أن يجري/ تُجري لك تقييمًا طبيًّا عامًّا يشمل وظائف الكبد.</p><p>إذا حدث لك أي من ذلك، <strong>أخبر طبيبك فورًا</strong><strong>.</strong></p><p>إذا كنت بصدد الخضوع لجراحة تحت تخدير كلي، فأبلغ الطبيب بأنك تتناول عقار ستاليفو.</p><p><strong>إذا شعرت بأنك بحاجة إلى التَّوقف عن استخدام عقار ستاليفو، يُرجى استشارة طبيبك أولًا</strong><strong>.</strong> قد يكون من الضَّروري خفض جرعة عقار ستاليفو تدريجيًّا، وإجراء تغييرات على دوائك الآخر المضاد لمرض الشلل الرعاش (مرض باركنسون)؛ وذلك لمنع حدوث الأعراض الجانبية والحفاظ على أعراض مرض الشلل الرعاش (مرض باركنسون) الذي تعاني منه من التفاقم.</p><p>كبار السن</p><p>يمكنك تناول عقار ستاليفو بدون تعديل الجرعة إذا كنت أكبر من 65 عامًا.</p><p>الأطفال والمراهقون</p><p>لم يتم التَّثبت من استخدام عقار ستاليفو في الأطفال والمراهقين تحت سن 18 عامًا وبالتَّالي لا يمكن التوصية باستخدامه.</p><p>&nbsp;</p><p>تناول هذا المستحضر مع أدوية أخرى أو أعشاب أو مكملات غذائية</p><p><strong>أخبر طبيبك أو الصيدلي الخاص بك</strong> إذا كنت تتناول أو تناولت مؤخرًا أيَّة أدوية أخرى، بما في ذلك أية أدوية خافضة لضغط الدَّم، الأدوية التي يتم صرفها دون وصفة طبية أو المنتجات العشبية.</p><p>يمكن أن يزيد عقار ستاليفو من التَّأثيرات والأعراض الجانبية لبعض الأدوية المضادة للاكتئاب وبعض الأدوية الأخرى. يشمل ذلك مثبطات أوكسيديز أحادي الأمين - أ (مثل: موكلوبيميد)، مضادات الاكتئاب ثلاثية الحلقات (مثل: أميتربتيلين) ومثبطات إعادة امتصاص نورأدرينالين (مثل: ديسيبرامين ومابروتيلين وفينلافاكسين)، بالإضافة إلى باروكسيتين وريميتيرول وأيزوبرينالين وأدرينالين ونورأدرينالين ودُوبامِين ودُوبيوتامِين وألفا ميثيل دوبا وآبومُورْفين.</p><p>راقب حدوث أية تأثيرات إضافية إذا كنت تتناول هذه الأدوية بينما تُعالج بعقار ستاليفو.</p><p>قد تضعف أدوية معينة من تأثيرات عقار ستاليفو. وهي تشمل الأدوية الآتية:</p><p>التي تُستخدم لعلاج الاضطرابات النفسية (مناهضات الدوبامين).</p><p>التي تُستخدم لعلاج الغثيان والقيء (مناهضات الدوبامين).</p><p>التي تُستخدم لمنع التشنجات (فينيتوين).</p><p>التي تُستخدم لإرخاء العضلات (بابافيرين).</p><p>أخبر طبيبك إذا كنت تتناول هذه الأدوية، أو إذا لاحظت أنَّ عقار ستاليفو لا يعمل بشكل جيد عندما تقوم بتناولها.</p><p>قد يسبب عقار ستاليفو صعوبة لك في هضم الحديد. لذا، لا تتناول عقار ستاليفو ومكملات الحديد في الوقت نفسه. بعد تناول أي منهم، انتظر على الأقل ساعتين إلى 3 ساعات قبل تناول الآخر.</p><p>&nbsp;</p><p>الحمل والرَّضاعة الطبيعية والخصوبة</p><p>إذا كنتِ حاملًا أو تعتقدين بأنك قد تكونين حاملًا، فلا تتناولي عقار ستاليفو قبل استشارة طبيبكِ. يجب عدم استخدام عقار ستاليفو أثناء الحمل ما لم تكن هناك ضرورة واضحة لذلك. سيناقش معك طبيبك الخطر المُحتمل الذي قد ينتج عن تناوُل عقار ستاليفو أثناء الحمل.</p><p>الأمهات المرضعات</p><p>أخبري طبيبكِ إذا كنتِ مرضعًا. يجب ألا ترضعين طبيعيًّا أثناء خضوعك للعلاج بعقار ستاليفو.</p><p>تأثير العقار على القيادة واستخدام الآلات</p><p>قد يسبب لك عقار ستاليفو انخفاضًا في ضغط الدَّم وهو ما قد يجعلك تشعر بخفة الرأس أو الدوخة. لذا، يجب أن تتوخى الحذر بشكل خاص عند القيادة أو عند تشغيل أي أدوات أو آلات.</p><p>إذا شعرت بنعاس شديد، أو وجدت نفسك غلبك النوم فجأة في بعض الأحيان، فيجب ألا تمارس القيادة أو تفعل أي شيء آخر يتطلب منك اليقظة (تشغيل الأدوات أو الآلات). يُرجى استشارة طبيبك. وإلا، فقد تعرض نفسك والآخرين لخطر حدوث إصابة خطيرة أو الوفاة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول دائمًا عقار ستاليفو حسب تعليمات طبيبك بالضبط. يجب مراجعة طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكدًا من طريقة التناول.</p><p>ما هي الكمية التي يجب أن تتناولها؟</p><p>يحتوي كل قرص من عقار ستاليفو على جرعة واحدة كاملة من ليفودوبا وكاربيدوبا وإنتاكابون. تَناوَل قرصًا واحدًا فقط في كل مرة تتناول فيها عقار ستاليفو. القرص غير معد للتقسيم أو التكسير إلى أجزاء أصغر.</p><p>سيخبرك طبيبك بالضبط كم عدد الأقراص التي يجب أن تتناولها من عقار ستاليفو كل يوم. قد يقترح طبيبك تناوُل جرعة أعلى أو أقل وفقًا لكيفية استجابتك للعلاج.</p><p>عقار ستاليفو 50/12.5/200 مجم و75/18.75/200 مجم و100/25/200 مجم و125/31.25/200 مجم و150/37.5/200 مجم: لا تتناول أكثر من 10 أقراص في اليوم.</p><p>عقار ستاليفو 175/43.75/200 مجم: لا تتناول أكثر من 8 أقراص في اليوم.</p><p>عقار ستاليفو 200/50/200 مجم: لا تتناول أكثر من 7 أقراص في اليوم.</p><p>تحدث إلى طبيبك أو الصيدلي الخاص بك إذا اعتقدت أنَّ تأثير عقار ستاليفو أقوى من اللازم أو أقل من اللازم، أو إذا اكتشفت أية أعراض جانبية محتملة.</p><p>توقيت وطريقة تناوُل عقار ستاليفو</p><p>اتبع بشدة تعليمات طبيبك فيما يتعلق بتوقيت وطريقة استخدام عقار ستاليفو والأدوية الأخرى التي تحتوي على ليفودوبا والعقاقير الأخرى المضادة لمرض الشلل الرعاش (مرض باركنسون). راجع طبيبك أو الصيدلي الخاص بك إذا كنت غير متأكد بشأن هذه التَّعليمات أو النَّص المطبوع على العبوة.</p><p>تناول عقار ستاليفو مع الطعام والشراب</p><p>يُمكن تناوُل عقار ستاليفو مع الطعام أو بدونه.</p><p>بالنسبة لبعض المرضى، قد لا يتم امتصاص عقار ستاليفو جيدًا إذا تم تناوله مع طعام غني بالبروتينات (مثل: اللحوم والأسماك ومنتجات الألبان والبذور والمكسرات) أو بعده بوقت قصير. يُرجى استشارة طبيبك إذا كنت تعتقد أنَّ هذا ينطبق عليك.</p><p>لا تتناول عقار ستاليفو ومكملات الحديد في الوقت نفسه. بعد تناول أي منهم، انتظر على الأقل ساعتين إلى 3 ساعات قبل تناول الآخر.</p><p>&nbsp; &zwnj;أ.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تناولت عقار ستاليفو أكثر مما يجب</p><p>إذا كنت قد تناولت كمية كبيرة جدًّا من أقراص عقار ستاليفو بطريق الخطأ، <strong>فتحدَّث إلى طبيبك</strong> <strong>على الفور</strong><strong>. </strong>قد تحتاج إلى الرعاية الطبية.</p><p>&nbsp;</p><p>&zwnj;ب.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نسيان تناوُل عقار ستاليفو</p><p>إذا كان متبقيًا على وقت جرعتك التالية أكثر من ساعة واحدة: فتناول قرصًا واحدًا الآن، والقرص التالي في الوقت المُعتاد.</p><p>إذا كان متبقيًّا على وقت جرعتك التالية أقل من ساعة واحدة: فتناول قرصًا الآن، وانتظر ساعة، ثم تناول قرصًا آخر. بعد ذلك استأنف تناول جرعاتك حسب جدولك المعتاد.</p><p>لا<strong> </strong>تتناول جرعة مضاعفة لتعويض الجرعات التي نسيتها. اترك دائمًا ساعة واحدة على الأقل بين تناول أقراص عقار ستاليفو، لمنع حدوث أية أعراض جانبية محتملة.</p><p>إذا كنت غير متأكد مما يجب عليك فعله، فاستشر طبيبك.</p><p>&zwnj;ج.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التَّوقف عن تناول عقار ستاليفو</p><p>لا تتوقف عن تناول عقار ستاليفو ما لم يخبرك طبيبك بذلك. في هذه الحالة، قد يحتاج طبيبك إلى إعادة تعديل جرعة الأدوية الأخرى المضادة لمرض الشلل الرعاش (مرض باركنسون) الخاصة بك، خاصةً ليفودوبا، للسيطرة على الأعراض التي تعاني منها بشكل كافٍ. التوقف المفاجئ عن تناول كل من عقار ستاليفو والأدوية الأخرى المضادة لمرض الشلل الرعاش (مرض باركنسون) من شأنه أن يسبب أعراضًا جانبية غير مرغوب فيها، مثل: التصلب العضلي الشديد والحمى المرتفعة وتغير الوعي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كما هو الحال مع كافة الأدوية، قد يتعرَّض المرضى الذين يتم علاجهم بعقار ستاليفو لأعراض جانبية، على الرَّغم من عدم حدوثها لدى الجميع. إذا عانيت من أي من هذه الأعراض الجانبية، تحدَّث إلى طبيبك بأسرع ما يمكن. يمكن تخفيف العديد من الأعراض الجانبية بتعديل الجرعة.</p><p><strong>اتصل بطبيبك على الفور</strong> إذا عانيت من الأعراض التَّالية أثناء العلاج بعقار ستاليفو:</p><p>تصلب شديد بعضلاتك أو كانت ترتعش بشدة، أو إذا عانيت من ارتعاش عضلي أو هياج أو ارتباك أو حمى أو تسارع النبض، أو تذبذبات كبيرة في ضغط الدَّم لديك. قد تكون هذه أعراض الإصابة بالمُتَلَازِمَة الخَبيثَة للدَّواءِ المُضادِّ للذُّهان (وهي تفاعل نادر وشديد تجاه الأدوية التي تستخدم لعلاج اضطرابات الجهاز العصبي المركزي) أو انحلال الربيدات (وهو اضطراب عضلي نادر وشديد).</p><p>تفاعل حساسية، قد تشمل العلامات شرى (طفح القراص)، حكة، طفحًا جلديًّا، تورم الوجه أو الشفتين أو اللسان أو الحلق لديك. قد يسبب ذلك صعوبات في التنفس أو البلع.</p><p>إذا لاحظت أية أعراض جانبية محتملة أخرى غير المذكورة في هذه النَّشرة، يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك.</p><p>شائعة جدًّا (<em>تُؤثر على أكثر من مستخدم واحد من بين كل </em><em>10 </em><em>مستخدمين</em>)</p><p>حركات لا يُمكِن التَّحكم بها (خَللُ الحَرَكَة).</p><p>الشعور بالإعياء (غثيان).</p><p>تغير غير مضر في لون البول إلى اللون البني المحمر.</p><p>ألم في العضلات.</p><p>إِسْهال.</p><p>شائعة (<em>تؤثر على مستخدم واحد إلى </em><em>10 </em><em>مستخدمين من بين كل </em><em>100 </em><em>مستخدم</em>)</p><p>أحداث مرضية بالقلب أو الشرايين بخلاف النوبة القلبية (مثل: ألم بالصدر)، عدم انتظام معدل ضربات القلب أو النظم القلبي.</p><p>شعور بخفة الرأس أو إغماء بسبب انخفاض ضغط الدَّم، ارتفاع ضغط الدَّم.</p><p>تفاقم أعراض مرض الشلل الرعاش (مرض باركنسون).</p><p>دوخة، نُعاس.</p><p>قيء، ألم بالبطن والشعور بعدم الراحة، حموضة، جفاف الفم، إمساك.</p><p>عدم القدرة على النوم، هلاوس، ارتباك، أحلام غير طبيعية، بما في ذلك الكوابيس، تغييرات نفسية، تشمل مشاكل في الذاكرة أو التفكير، قلق واكتئاب (ربما يكون مصحوبًا بأفكار انتحارية)، تعب، ألم بالصدر.</p><p>السقوط بشكل أكثر تكرارًا، خلل في المشي، فقدان كلٍّ من القوة والطاقة.</p><p>ضيق التنفس.</p><p>زيادة التعرُّق، حالات من الطفح الجلدي.</p><p>تقلصات عضلية، انقباضات عضلية غير إرادية، تورم الساقين.</p><p>عدم وضوح الرؤية.</p><p>فقر الدَّم، انخفاض الشهية، نقص الوزن.</p><p>صداع، ألم بالمفاصل.</p><p>عدوى بالجهاز البولي.</p><p>غير شائعة (<em>تؤثر على مستخدم واحد إلى </em><em>10 </em><em>مستخدمين من بين كل </em><em>1000 </em><em>مستخدم</em>)</p><p>نوبة قلبية.</p><p>نزيف بالأمعاء.</p><p>نتائج غير طبيعية باختبارات وظائف الكبد، أعراض ذهانية، الشعور بهياج.</p><p>التهاب القَولون.</p><p>تغير في لون الجلد والأظافر والشعر والعرق.</p><p>تغيرات في عدد خلايا الدَّم مما قد يُؤدي إلى حدوث نزيف.</p><p>صعوبات بالبلع.</p><p>عدم القدرة على التبول.</p><p>شعور عام بالإعياء.</p><p>بعض الأعراض الجانبية التي قد تكون نادرة أو نادرة جدًّا</p><p>تشنجات.</p><p>أعراض جانبية أخرى</p><p>معدّلات التكرار الدقيقة لهذه الأعراض الجانبية غير معروفة ولكنها تستند إلى التقارير التي تم تلقيها منذ أن طُرح المنتج بالأسواق:</p><p>التهاب الكبد.</p><p>حكة.</p><p>نيمومة مفرطة بالنهار، بداية نوبات نوم مفاجئة.</p><p>قد تعاني من الأعراض الجانبية التَّالية:</p><p>الرغبة الشديدة في تناول جرعات كبيرة من عقار ستاليفو أكثر من تلك المطلوبة؛ للتحكم في الأعراض الحركية، وهي ما تسمى بمتلازمة خلل تنظيم الدوبامين. يعاني بعض المرضى من حركات شديدة لا يُمكِن التحكم بها (خَللُ الحَرَكَة) أو تغيرات في الحالة المزاجية أو أعراض جانبية أخرى بعد تناول جرعات كبيرة من عقار ستاليفو.</p><p>عدم القدرة على مقاومة الاندفاع للقيام بفعل قد يكون ضارًّا، والتي قد تشمل ما يلي:</p><p>الاندفاع القوي للعب القمار على نحوٍ مفرط برغم العواقب الوخيمة أو العواقب الأسرية الشخصية.</p><p>تغير أو ازدياد في الرغبة والسلوك الجنسي لتصبح مصدر قلق كبير &nbsp;بالنسبة لك أو للآخرين مثل ازدياد الدافع الجنسي.</p><p>الإفراط في التسوق أو الإنفاق بشكل لا يمكن السيطرة عليه.</p><p>الشراهة (تناول كميات كبيرة من الطعام في فترة زمنية قصيرة) أو الأكل القهري (تناول كمية من الطعام تزيد عن الكمية الطبيعية وعن الكمية اللازمة لإشباع جوعك).</p><p>أخبر طبيبك إذا كنت تعاني من أي من هذه السلوكيات؛ وسيناقش طبيبك طرق علاج الأعراض أو تقليلها.</p><p><strong>إذا أصبح أي من الأعراض الجانبية خطيرًا، فأخبر طبيبك أو الممرض</strong><strong>(ة</strong><strong>) أو الصيدلي الخاص بك</strong><strong>.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا توجد ظروف خاصة للتخزين.</p><p>لا تستخدم هذا الدَّواء بعد انتهاء تاريخ الصلاحية المطبوع على العبوة.</p><p>لا تستخدم هذا الدَّواء إذا كانت العبوة تالفة أو بدى عليها علامات العبث.</p><p>يُحفظ بعيدًا عن مُتناوَل ورؤية الأطفال.</p><p>لا يُخزَّن في درجة حرارة تتعدى 30 درجة مئوية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>عقار ستاليفو 50/12.5/200 مجم و100/25/200 مجم و150/37.5/200 مجم و200/50/200 مجم أقراص مغلَّفة</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المواد الفعالة</strong> لعقار ستاليفو هي ليفودوبا وكاربيدوبا وإنتاكابون.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المكونات الأخرى</strong> هي كروسكارميلوز الصوديوم وستيرات الماغنسيوم ونشا الذرة ومانِّيتول وبوفيدون وجليسيرُول 85٪ وهيبروميلوز وبوليسوربات 80 وأكسيد الحديد الأحمر (E 172) وسكروز وثاني أكسيد التيتانيوم (E 171) وأكسيد الحديد الأصفر (E 172).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            يحتوي عقار ستاليفو على ثلاث مواد فعالة في قرص مغلف واحد. كل قرص يحتوي على ليفودوبا، وهي مادة تستخدم لعلاج مرض الشلل الرعَّاش (مرض باركنسون). المادتان الفعالتان الأخرتان هما: كاربيدوبا وإنتاكابون وهما مادتان تحسنان تأثيرات ليفودوبا المضادة لمرض الشلل الرعاش (مرض باركنسون).
يتوفر عقار ستاليفو في أربعة تركيزات مختلفة للجرعة: 50/12.5/200 مجم و100/25/200 مجم و150/37.5/200 مجم و200/50/200 مجم أقراص مغلفة ويأتي في عبوة بحجم 30 قرصًا 
أقراص عقار ستاليفو عليها غلاف رقيق ذو لون أحمر بني يميل إلى الرمادي فوق محتوى داخلي برتقالي مائل إلى الأصفر.
عقار ستاليفو أقراص 50/12.5/200 مجم: أقراص ذات لون أحمر بني مائل إلى الرمادي، مستديرة الشكل، محدبة، على أحد جانبيها العلامة "LCE 50".
عقار ستاليفو 100/25/200 مجم: أقراص ذات لون أحمر بني مائل إلى الرمادي، بيضاوية الشكل، على أحد جانبيها العلامة "LCE 100".
عقار ستاليفو 150/37.5/200 مجم: أقراص ذات لون أحمر بني مائل إلى الرمادي، ذات شكل بيضاوي مستطيل، على أحد جانبيها العلامة "LCE 150".
عقار ستاليفو 200/50/200 مجم: أقراص ذات لون أحمر داكن يميل إلى البني، بيضاوية الشكل، على أحد جانبيها العلامة "LCE 200". 

        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مالك حق التسويق لهذا المنتج هي شركة نوفارتس فارما.</p><p>www.Novartis.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ‌د.	تم آخر اعتماد لهذه النشرة من قبل شركة نوفارتس للأدوية في 05/2019.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                STALEVO 50 mg/12.5 mg/200 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Stalevo® 50 mg/12.5 mg/200 mg: each tablet contains 50 mg of levodopa, 12.5 mg of carbidopa and 200 mg of entacapone.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.

Stalevo 50 mg/12.5 mg/200 mg: brownish- or greyish-red, round, convex, unscored film-coated tablets marked with ‘LCE 50’ on one side

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Stalevo is indicated for the treatment of patients with Parkinson&rsquo;s disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The optimum daily dosage must be determined by careful titration of levodopa in each patient. The daily dose should preferably be optimised using one of the seven available tablet strengths (50/12.5/200 mg, 75/18.75/200 mg, 100/25/200 mg, 125/31.25/200 mg, 150/37.5/200 mg, 175/43.75/200 mg or 200/50/200 mg levodopa/ carbidopa/ entacapone).</p><p>Patients should be instructed to take only one Stalevo tablet per dose administration. Patients receiving less than 70-100 mg carbidopa a day are more likely to experience nausea and vomiting. While the experience with total daily dosage greater than 200 mg carbidopa is limited, the maximum recommended daily dose of entacapone is 2000 mg and therefore the maximum Stalevo dose, for the Stalevo strengths of 50/12.5/200 mg, 75/18.75/200 mg, 100/25/200 mg, 125/31.25/200 mg and 150/37.5/200 mg, is 10 tablets per day. Ten (10) tablets of Stalevo 150/37.5/200 mg equals 375 mg of carbidopa a day. Therefore, using a maximum recommended daily dose of 375 mg of carbidopa, the maximum daily dose of Stalevo 175/43.75/200 mg dose is 8 tablets per day and Stalevo 200/50/200 mg is 7 tablets per day.</p><p>The maximum total daily levodopa dose administered in the form of Stalevo should not exceed 1500 mg.</p><p>Starting Stalevo therapy</p><p>Switching from levodopa/ DDC inhibitor (carbidopa or benserazide) preparations and entacapone to Stalevo</p><p>Usually Stalevo is intended for use in patients already receiving treatment with corresponding doses of standard-release levodopa/DDC inhibitor and entacapone.</p><p>As with levodopa/carbidopa, non-selective monoamine oxidase (MAO) inhibitors are contraindicated for use with Stalevo. These inhibitors must be discontinued at least two weeks prior to initiating therapy with Stalevo. Stalevo may be administered concomitantly with the manufacturer&rsquo;s recommended dose of MAO inhibitors with selectivity for MAO type B (e.g., selegiline HCl).</p><p><em>a</em>.&nbsp; Patients who are currently receiving treatment with entacapone and standard-release levodopa/carbidopa in doses equal to Stalevo tablet strengths can be directly switched to the corresponding Stalevo tablets, for example:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:94%"><tbody><tr><td style="vertical-align:top"><p><strong>Levodopa/Carbidopa</strong></p></td><td style="vertical-align:top"><p><strong>Entacapone</strong></p></td><td style="vertical-align:top"><p><strong>Equivalent Stalevo</strong></p></td></tr><tr><td style="vertical-align:top"><p>50/12.5 mg</p></td><td style="vertical-align:top"><p>200 mg</p></td><td style="vertical-align:top"><p>50/12.5/200 mg</p></td></tr><tr><td style="vertical-align:top"><p>100/25 mg</p></td><td style="vertical-align:top"><p>200 mg</p></td><td style="vertical-align:top"><p>100/25/200 mg</p></td></tr><tr><td style="vertical-align:top"><p>150/37.5 mg</p></td><td style="vertical-align:top"><p>200 mg</p></td><td style="vertical-align:top"><p>150/37.5/200 mg</p></td></tr><tr><td style="vertical-align:top"><p>200/50 mg</p></td><td style="vertical-align:top"><p>200 mg</p></td><td style="vertical-align:top"><p>200/50/200 mg</p></td></tr></tbody></table><p><em>b.</em>&nbsp; When initiating Stalevo therapy in patients currently receiving treatment with entacapone and levodopa/carbidopa in doses not equal to the available Stalevo tablet strengths (50/12.5/200&nbsp;mg, 75/18.75/200 mg, 100/25/200&nbsp;mg, 125/31.25/200 mg, 150/37.5/200&nbsp;mg, 175/43.75/200 mg or 200/50/200 mg), Stalevo dosing should be carefully titrated for optimal clinical response. At the start of therapy, Stalevo should be adjusted to correspond as closely as possible to the total daily dose of levodopa currently used.</p><p><em>c.</em>&nbsp; When initiating Stalevo in patients currently treated with entacapone and levodopa/benserazide in a standard-release formulation, treatment should be stopped for one night and Stalevo therapy started the next morning. The therapy should begin with a dosage of Stalevo that will provide either the same amount of levodopa or slightly (5-10%) more.</p><p>Switching in patients not currently treated with entacapone to Stalevo</p><p>As with levodopa/carbidopa, non-selective monoamine oxidase (MAO) inhibitors are contraindicated for use with Stalevo. These inhibitors must be discontinued at least two weeks prior to initiating therapy with Stalevo. Stalevo may be administered concomitantly with the manufacturer&rsquo;s recommended dose of MAO inhibitors with selectivity for MAO type B (e.g., selegiline HCl).</p><p>Initiation of Stalevo at a dosage corresponding to current treatment may be considered in some patients with Parkinson&#39;s disease and end-of-dose motor fluctuations who are not stabilised on their current standard-release levodopa/DDC inhibitor treatment. However, a direct switch from levodopa/DDC inhibitor to Stalevo is not recommended for patients who have dyskinesias or whose daily levodopa dose is above 800&nbsp;mg. In such patients it is advisable to introduce entacapone treatment as a separate medication (entacapone tablets) and adjust the levodopa dose if necessary, before switching to Stalevo.</p><p>Entacapone enhances the effects of levodopa. It may therefore be necessary, particularly in patients with dyskinesia, to reduce levodopa dosage by 10-30% within the first days to first weeks after initiating Stalevo treatment. The daily dose of levodopa can be reduced by extending the dosing intervals and/or by reducing the amount of levodopa per dose, according to the clinical condition of the patient.</p><p>Dosage adjustment during the course of the treatment</p><p>When more levodopa is required, an increase in the frequency of doses and/or the use of an alternative strength of Stalevo should be considered, within the dosage recommendations.</p><p>When less levodopa is required, the total daily dosage of Stalevo should be reduced either by decreasing the frequency of administration by extending the time between doses, or by decreasing the strength of Stalevo at an administration.</p><p>If other levodopa products are used concomitantly with a Stalevo tablet, the maximum dosage recommendations should be followed.</p><p>Discontinuation of Stalevo therapy</p><p>If Stalevo treatment (levodopa/carbidopa/entacapone) is discontinued and the patient is switched to levodopa/DDC inhibitor therapy without entacapone, it is necessary to adjust the dosing of other antiparkinsonian treatments, especially levodopa, to achieve a sufficient level of control of the parkinsonian symptoms (see section SPECIAL WARNINGS AND PRECAUTIONS FOR USE, rhabdomyolysis).</p><p>Children and adolescents</p><p>The safety and efficacy of Stalevo in children aged below 18 years have not been established. No data are available.</p><p>Elderly</p><p>No adjustment of Stalevo dosage is necessary in elderly patients.</p><p>Hepatic impairment</p><p>Caution is recommended when administering Stalevo to patients with mild to moderate hepatic impairment. Dose reduction may be necessary (see section PHARMACOKINETICS).</p><p>Renal impairment</p><p>Renal impairment does not affect the pharmacokinetics of entacapone. No specific studies are reported on the pharmacokinetics of levodopa and carbidopa in patients with renal impairment, and Stalevo should therefore be administered with caution in patients with severe renal impairment including those receiving dialysis therapy (see section PHARMACOKINETICS).</p><p>Method of administration</p><p>Each tablet is to be taken orally either with or without food (see section PHARMACOKINETICS). One tablet contains one treatment dose and the tablet may only be administered as whole tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Known hypersensitivity to the active substances or to any of the excipients.
•	Severe hepatic impairment.
•	Narrow-angle glaucoma.
•	Pheochromocytoma.
•	Co-administration of a non-selective monoamine oxidase (MAO-A and MAO-B) inhibitor (e.g. phenelzine, tranylcypromine).
•	Co-administration of a selective MAO-A inhibitor and a selective MAO-B inhibitor (see section INTERACTIONS, other antiparkinsonian medicinal products). These inhibitors must be discontinued at least two weeks prior to initiating therapy with Stalevo.
•	A history of Neuroleptic Malignant Syndrome (NMS) and/or non-traumatic rhabdomyolysis.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Stalevo is not recommended for the treatment of drug-induced extrapyramidal reactions.</p><p>Stalevo therapy should be administered with caution to patients with ischemic heart disease, severe cardiovascular or pulmonary disease, bronchial asthma, renal, hepatic or endocrine disease, or history of peptic ulcer disease or convulsions.</p><p>In patients with a history of myocardial infarction who have residual atrial nodal, or ventricular arrhythmias, cardiac function should be monitored with particular care during the period of initial dosage adjustments.</p><p>All patients treated with Stalevo should be monitored carefully for the development of mental changes (e.g. hallucinoses and psychoses), depression with suicidal tendencies, and serious antisocial behaviour. Patients with past or current psychosis should be treated with caution.</p><p>Concomitant administration of antipsychotics with dopamine receptor-blocking properties, particularly D<sub>2</sub> receptor antagonists, should be carried out with caution and the patient carefully observed for loss of antiparkinsonian effect or worsening of parkinsonian symptoms.</p><p>Patients with chronic wide-angle glaucoma may be treated with Stalevo with caution, provided the intra-ocular pressure is well controlled and the patient is monitored carefully for changes in intra-ocular pressure.</p><p>Stalevo may induce orthostatic hypotension. Therefore caution is necessary when giving Stalevo to patients who are taking other medicinal products which may cause orthostatic hypotension.</p><p>Entacapone in combination with levodopa has been associated with somnolence and episodes of sudden sleep onset in patients with Parkinson&rsquo;s disease and caution should therefore be exercised when driving or operating machines (see also section EFFECTS ON ABILITY TO DRIVE AND USE MACHINES).</p><p>In clinical studies, undesirable dopaminergic effects, e.g. dyskinesia, were more common in patients who received entacapone and dopamine agonists (such as bromocriptine), selegiline or amantadine compared to those who received placebo with this combination. The doses of other antiparkinsonian medicinal products may need to be adjusted when Stalevo is introduced in a patient not previously treated with entacapone.</p><p>Rhabdomyolysis secondary to severe dyskinesias or Neuroleptic Malignant Syndrome (NMS) has been observed rarely in patients with Parkinson&rsquo;s disease. Isolated cases of rhabdomyolysis have been reported with entacapone treatment. NMS, including rhabdomyolysis and hyperthermia, is characterised by motor symptoms (rigidity, myoclonus, tremor), mental status changes (e.g., agitation, confusion, coma), hyperthermia, autonomic dysfunction (tachycardia, labile blood pressure) and elevated serum creatine phosphokinase. In individual cases, only some of these symptoms and/or findings may be evident. Early diagnosis is important for the appropriate management of NMS. A syndrome resembling NMS including muscular rigidity, elevated body temperature, mental changes and increased serum creatine phosphokinase has been reported with the abrupt withdrawal of antiparkinsonian agents. Isolated cases of NMS have been reported, especially following abrupt reduction or discontinuation of entacapone.</p><p>When considered necessary, withdrawal of Stalevo and other dopaminergic treatment should proceed slowly, and if signs and/or symptoms occur despite a slow withdrawal of Stalevo, an increase in levodopa dosage may be necessary.</p><p>Prescribers should exercise caution when switching patients from Stalevo to levodopa/DDC inhibitor therapy without entacapone. When considered necessary, the replacement of Stalevo with levodopa and DDC inhibitor without entacapone should proceed slowly and an increase in levodopa dosage may be necessary.</p><p>If general anaesthesia is required, therapy with Stalevo may be continued for as long as the patient is permitted to take fluids and medication by mouth. If therapy has to be stopped temporarily, Stalevo may be restarted as soon as oral medication can be taken at the same daily dosage as before.</p><p>Periodic evaluation of hepatic, haematopoietic, cardiovascular and renal function is recommended during extended therapy with Stalevo.</p><p>For patients experiencing diarrhoea, a follow-up of weight is recommended in order to avoid potential excessive weight decrease. Prolonged or persistent diarrhoea suspected to be related to Stalevo may be a sign of colitis. In the event of prolonged or persistent diarrhoea, the drug should be discontinued and appropriate medical therapy and investigations considered.</p><p>For patients who experience progressive anorexia, asthenia and weight decrease within a relatively short period of time, a general medical evaluation including liver function should be considered.</p><p>Dopamine dysregulation syndrome (DDS) is an addictive disorder resulting in excessive use of the product seen in some patients treated with levodopa/carbidopa. Before initiation of treatment, patients and caregivers should be warned of the potential risk of developing DDS (see section UNDESIRABLE EFFECTS)</p><p>Patients should be regularly monitored for the development of impulse control disorders. Patients and caregivers should be made aware that behavioural symptoms of impulse control disorders including pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and/or other dopaminergic treatments containing levodopa including Stalevo. Review of treatment is recommended if such symptoms develop.</p><p>Levodopa/carbidopa may cause false positive result when a dipstick is used to test for urinary ketone and this reaction is not altered by boiling the urine sample. The use of glucose oxidase methods may give false negative results for glycosuria.</p><p>Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Other antiparkinsonian medicinal products</p><p>To date there has been no indication of interactions that would preclude concurrent use of standard antiparkinsonian medicinal products with Stalevo therapy. Entacapone in high doses may affect the absorption of carbidopa. However, no interaction with carbidopa has been observed with the recommended treatment schedule (200 mg of entacapone up to 10 times daily). Interactions between entacapone and selegiline have been investigated in repeated dose studies in Parkinson&#39;s disease patients treated with levodopa/DDC inhibitor and no interaction was observed. When used with Stalevo, the daily dose of selegiline should not exceed 10 mg.</p><p>Because Stalevo contains entacapone, it should not be used concurrently with Comtan (entacapone).</p><p>Caution should be exercised when the following active substances are administered concomitantly with levodopa therapy.</p><p>Antihypertensives</p><p>Symptomatic postural hypotension may occur when levodopa is initiated in patients already receiving antihypertensives. Dosage adjustment of the antihypertensive agent may be required.</p><p>Antidepressants</p><p>Rarely, reactions including hypertension and dyskinesia have been reported with the concomitant use of tricyclic antidepressants and levodopa/carbidopa. Interactions between entacapone and imipramine and between entacapone and moclobemide have been investigated in single dose studies in healthy volunteers. No pharmacodynamic interactions were observed. A significant number of Parkinson&#39;s disease patients have been treated with the combination of levodopa, carbidopa and entacapone with several active substances including MAO-A inhibitors, tricyclic antidepressants, noradrenaline reuptake inhibitors such as desipramine, maprotiline and venlafaxine and medicinal products that are metabolised by COMT (e.g. catechol-structured compounds: rimiterole, isoprenaline, adrenaline, noradrenaline, dopamine, dobutamine, alpha-methyldopa, apomorphine, and paroxetine). No pharmacodynamic interactions have been observed. However, caution should be exercised when these medicinal products are used concomitantly with Stalevo (see also section CONTRAINDICATIONS and section SPECIAL WARNINGS AND PRECAUTIONS FOR USE).</p><p>Other active substances</p><p>Dopamine receptor antagonists (e.g. some antipsychotics and antiemetics), phenytoin and papaverine may reduce the therapeutic effect of levodopa. Patients taking these medicinal products with Stalevo should be carefully observed for loss of therapeutic response.</p><p>Due to entacapone&#39;s affinity to cytochrome P450 2C9 <em>in vitro</em> (see section PHARMACOKINETICS), Stalevo may potentially interfere with active substances whose metabolism is dependent on this isoenzyme, such as S-warfarin. However, in an interaction study with healthy volunteers, entacapone did not change the plasma levels of S-warfarin, while the AUC for R-warfarin increased on average by 18 % [CI<sub>90</sub> 11-26 %]. The INR values increased on average by 13 % [CI<sub>90</sub> 6-19 %]. Thus, a control of INR is recommended when Stalevo is initiated in patients receiving warfarin.</p><p>Other forms of interactions</p><p>Since levodopa competes with certain amino acids, the absorption of Stalevo may be impaired in some patients on a high protein diet.</p><p>Levodopa and entacapone may form chelates with iron in the gastrointestinal tract. Therefore, Stalevo and iron preparations should be taken at least 2-3 hours apart (see section UNDESIRABLE EFFECTS).</p><p>Stalevo may be given to patients with Parkinson&#39;s disease who are taking vitamin preparations that contain pyridoxine hydrochloride (Vitamin B6).</p><p><em>In vitro</em> data</p><p>Entacapone binds to human albumin binding site II which also binds several other medicinal products, including diazepam and ibuprofen. According to <em>in vitro</em> studies, significant displacement is not anticipated at therapeutic concentrations of the medicinal products. Accordingly, to date there has been no indication of such interactions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p>There are no adequate data from the use of the combination of levodopa/carbidopa/entacapone in pregnant women. Studies in animals have shown reproductive toxicity of the separate compounds (see section PRECLINICAL SAFETY DATA). The potential risk for humans is unknown. Stalevo should not be used during pregnancy.</p><p>Breast-feeding</p><p>Levodopa is excreted in human breast milk. There is evidence that lactation is suppressed during treatment with levodopa. Carbidopa and entacapone were excreted in milk in animals but it is not known whether they are excreted in human breast milk. The safety of levodopa, carbidopa or entacapone in the infant is not known. Women should not breast-feed during treatment with Stalevo.</p><p>Fertility</p><p>No adverse reactions on fertility were observed in preclinical studies with entacapone, carbidopa or levodopa alone. Fertility studies in animals have not been conducted with the combination of entacapone, levodopa and carbidopa.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Stalevo may have a major influence on the ability to drive and use machines. Patients being treated with Stalevo and presenting with somnolence and/or sudden sleep onset episodes must be instructed to refrain from driving or engaging in activities where impaired alertness may put themselves or others at risk of serious injury or death (e.g. operating machines) until such recurrent episodes have resolved (see also section&nbsp;SPECIAL WARNINGS AND PRECAUTIONS FOR USE).</p><p>Levodopa, carbidopa and entacapone together may cause dizziness and symptomatic orthostatism. Therefore, caution should be exercised when driving or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>a. Summary of the safety profile</strong></p><p>The most frequently reported adverse reactions with Stalevo are dyskinesias occurring in approximately 19% of patients; gastrointestinal symptoms including nausea and diarrhoea occurring in approximately 15% and 12% of patients, respectively; muscle, musculoskeletal and connective tissue pain occurring in approximately 12% of patients; and harmless reddish-brown discolouration of urine (chromaturia) occurring in approximately 10% of patients. Serious events of gastrointestinal haemorrhage (uncommon) and angioedema (rare) have been identified from the clinical trials with Stalevo or entacapone combined with levodopa/DDC inhibitor. Serious hepatitis with mainly cholestatic features, rhabdomyolysis and neuroleptic malignant syndrome may occur with Stalevo although no cases have been identified from the clinical trial data.</p><p><strong>b. Tabulated list of adverse reactions</strong></p><p>The following adverse reactions, listed in Table 1, have been accumulated both from a pooled data of eleven double-blind clinical trials consisting of 3230 patients (1810 treated with Stalevo or entacapone combined with levodopa/DDC inhibitor, and 1420 treated with placebo combined with levodopa/DDC inhibitor or cabergoline combined with levodopa/ DDC inhibitor), and from the post-marketing data since the introduction of entacapone into the market for the combination use of entacapone with levodopa/DDC inhibitor.</p><p>Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data, since no valid estimate can be derived from clinical trials or epidemiological studies).</p><p>Table 1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse reactions</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Anaemia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Thrombocytopenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Weight decreased*, decreased appetite*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Depression, hallucination, confusional state*, abnormal dreams*, anxiety, insomnia,</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon&nbsp;:</p></td><td style="vertical-align:top"><p>Psychosis, agitation*</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Suicidal behaviour, dopamine dysregulation syndrome</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:&nbsp;</p></td><td style="vertical-align:top"><p>Dyskinesia*</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Parkinsonism aggravated (e.g. bradykinesia)*,tremor, on and off phenomenon, dystonia, mental impairment (e.g. memory impairment, dementia), somnolence, dizziness*, headache</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Neuroleptic malignant syndrome*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Blurred vision</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Ischemic heart disease events other than myocardial infarction (e.g. angina pectoris)**, irregular heart rhythm</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Myocardial infarction**</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders:</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Orthostatic hypotension, hypertension</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Gastrointestinal haemorrhage</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Dyspnoea</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Diarrhoea*, nausea*</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Constipation*, vomiting*, dyspepsia, abdominal pain and discomfort*, dry mouth*</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Colitis*, dysphagia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Hepatic function test abnormal*</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Hepatitis with mainly cholestatic features (see section SPECIAL WARNINGS AND PRECAUTIONS FOR USE)*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Rash*, hyperhidrosis</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Discolourations other than urine (e.g. skin, nail, hair, sweat)*</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Angioedema</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Urticaria*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:&nbsp;</p></td><td style="vertical-align:top"><p>Muscle, musculoskeletal and connective tissue pain*</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Muscle spasms, arthralgia</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Rhabdomyolysis*</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Chromaturia*</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Urinary tract infection</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Urinary retention</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Chest pain, peripheral oedema, fall,&nbsp; gait disturbance,&nbsp; asthenia, fatigue</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Malaise</p></td></tr></tbody></table><p>*Adverse reactions that are mainly attributable to entacapone or are more frequent (by the frequency difference of at least 1% in the clinical trial data) with entacapone than levodopa/DDC inhibitor alone. See section c.</p><p>**The incidence rates of myocardial infarction and other ischemic heart disease events&nbsp;(0.43% and 1.54%, respectively) are derived from an analysis of 13 double-blind studies involving 2082 patients with end-of-dose motor fluctuations receiving entacapone.</p><p><strong>c. Description of selected adverse reactions</strong></p><p>Adverse reactions that are mainly attributable to entacapone or are more frequent with entacapone than levodopa/DDC inhibitor alone are indicated with an asterisk in Table 1, section 4.8b. Some of these adverse reactions relate to the increased dopaminergic activity (e.g. dyskinesia, nausea and vomiting) and occur most commonly at the beginning of the treatment. Reduction of levodopa dose decreases the severity and frequency of these dopaminergic reactions. Few adverse reactions are known to be directly attributable to the active substance entacapone including diarrhoea and reddish-brown discolouration of urine. Entacapone may in some cases cause also discolouration of e.g. skin, nail, hair and sweat.</p><p>Other adverse reactions with an asterisk in Table 1, section 4.8b are marked based on either their more frequent occurrence (by the frequency difference of at least 1%) in the clinical trial data with entacapone than levodopa/DDCI alone or the individual case safety reports received after the introduction of entacapone into the market.</p><p>Convulsions have occurred rarely with levodopa/carbidopa; however a causal relationship to levodopa/carbidopa therapy has not been established.</p><p>Dopamine dysregulation syndrome (DDS) is an addictive disorder seen in some patients treated with levodopa/carbidopa. Affected patients show a compulsive pattern of dopaminergic drug misuse above doses adequate to control motor symptoms, which may in some cases result in severe dyskinesias (see section SPECIAL WARNINGS AND PRECAUTIONS FOR USE)</p><p>Impulse control disorders: pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and/or other dopaminergic treatments containing levodopa including Stalevo (see section SPECIAL WARNINGS AND PRECAUTIONS FOR USE).</p><p>Entacapone in association with levodopa has been associated with isolated cases of excessive daytime somnolence and sudden sleep onset episodes.</p><p>&nbsp;</p><p><strong>--<em>To reports any side effect(s): </em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp; <strong><em>Saudi Arabia: </em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Food and Drug Authority National Pharmacovigilance Center (NPC):</p><p>o Fax: +966112057662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p>o Toll free phone: 8002490000</p><p>o SFDA call center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>O Toll Free Number: 8001240078</p><p>O Phone: +966112658100<br />O Fax: +966112658107<br /><strong><em>O Email: </em></strong><strong><em>adverse.events@novartis.com</em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp; <strong><em>Other GCC States: </em></strong></p><p>-- Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The post-marketing data includes isolated cases of overdose in which the reported highest daily doses of levodopa and entacapone have been at least 10,000 mg and 40,000 mg, respectively. The acute symptoms and signs in these cases of overdose included agitation, confusional state, coma, bradycardia, ventricular tachycardia, Cheyne-Stokes respiration, discolourations of skin, tongue and conjunctiva, and chromaturia.</p><p>Management of acute overdosage with Stalevo is similar to acute overdosage with levodopa. Hospitalisation is advised and general supportive measures should be employed with immediate gastric lavage and repeated doses of charcoal over time. This may hasten the elimination of entacapone in particular by decreasing its absorption/reabsorption from the gastrointestinal tract. The adequacy of the respiratory, circulatory and renal systems should be carefully monitored and appropriate supportive measures employed. ECG monitoring should be started and the patient carefully monitored for the possible development of arrhythmias. If required, appropriate anti-arrhythmic therapy should be given. The possibility that the patient has taken other active substances in addition to Stalevo should be taken into consideration. The value of dialysis in the treatment of overdosage is not known.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>According to current understanding, the symptoms of Parkinson&rsquo;s disease are related to depletion of dopamine in the corpus striatum. Dopamine does not cross the blood-brain barrier. Levodopa, the precursor of dopamine, crosses the blood brain barrier and relieves the symptoms of the disease. As levodopa is extensively metabolised in the periphery, only a small portion of a given dose reaches the central nervous system when levodopa is administered without metabolic enzyme inhibitors.</p><p>Carbidopa and benserazide are peripheral DDC inhibitors which reduce the peripheral metabolism of levodopa to dopamine, resulting in an increase in the amount of levodopa available to the brain. When decarboxylation of levodopa is reduced with the co-administration of a DDC inhibitor, a lower dose of levodopa can be used and the incidence of adverse reactions such as nausea is reduced.</p><p>With the inhibition of the decarboxylase by a DDC inhibitor, COMT becomes the major peripheral metabolic pathway catalyzing the conversion of levodopa to 3-O-methyldopa (3-OMD), a potentially harmful metabolite of levodopa. Entacapone is a reversible, specific and mainly peripherally acting COMT inhibitor designed for concomitant administration with levodopa. Entacapone slows the clearance of levodopa from the bloodstream resulting in an increased area under the curve (AUC) in the pharmacokinetic profile of levodopa. Consequently the clinical response to each dose of levodopa is enhanced and prolonged.</p><p>The evidence of the therapeutic effects of Stalevo is based on two phase III double-blind studies, in which 376 Parkinson&rsquo;s disease patients with end-of-dose motor fluctuations received either entacapone or placebo with each levodopa/DDC inhibitor dose. Daily ON time with and without entacapone was recorded in home-diaries by patients. In the first study, entacapone increased the mean daily ON time by 1 h 20 min (CI <sub>95%</sub> 45 min, 1h 56min) from baseline. This corresponded to an 8.3% increase in the proportion of daily ON time. Correspondingly, the decrease in daily OFF time was 24% in the entacapone group and 0% in the placebo group. In the second study, the mean proportion of daily ON time increased by 4.5% (CI <sub>95%</sub> 0.93%, 7.97%) from baseline. This is translated to a mean increase of 35 min in the daily ON time. Correspondingly, the daily OFF time decreased by 18% on entacapone and by 5% on placebo. Because the effects of Stalevo tablets are equivalent with entacapone 200 mg tablet administered concomitantly with the commercially available standard release carbidopa/levodopa preparations in corresponding doses these results are applicable to describe the effects of Stalevo as well.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>General characteristics of the active substances</p><p>Absorption/Distribution</p><p>There are substantial inter- and intra-individual variations in the absorption of levodopa, carbidopa<sup> </sup>and entacapone. Both levodopa and entacapone are rapidly absorbed and eliminated. Carbidopa is absorbed and eliminated slightly more slowly than levodopa. When given separately without the other two active substances, the bioavailability of levodopa is 15-33%, that of carbidopa 40-70% and that of entacapone 35% after a 200 mg oral dose. Meals rich in large neutral amino acids may delay and reduce the absorption of levodopa. Food does not significantly affect the absorption of entacapone. The distribution volume of both levodopa (Vd 0.36 - 1.6 L/kg) and entacapone (Vd<sub>ss</sub> 0.27 L/kg) is moderately small; no data are available for carbidopa.</p><p>Levodopa is bound to plasma proteins only to a minor extent (about 10-30%), while carbidopa is bound approximately 36%, and while entacapone is extensively bound (about 98%), mainly to serum albumin. At therapeutic concentrations, entacapone does not displace other extensively bound active substances (e.g. warfarin, salicylic acid, phenylbutazone, or diazepam), nor is it displaced to any significant extent by any of these substances at therapeutic or higher concentrations.</p><p>Metabolism and Elimination</p><p>Levodopa is extensively metabolised to various metabolites, decarboxylation by dopa decarboxylase (DDC) and O-methylation by catechol-O-methyltransferase (COMT) being the most important pathways.</p><p>Carbidopa is metabolised to two main metabolites which are excreted in the urine as glucuronides and unconjugated compounds. Unchanged carbidopa accounts for 30% of the total urinary excretion.</p><p>Entacapone is almost completely metabolised prior to excretion via urine (10 to 20%) and bile/faeces (80 to 90%). The main metabolic pathway is glucuronidation of entacapone and its active metabolite, the cis-isomer, which accounts for about 5% of the total amount in plasma.</p><p>Total clearance of levodopa is in the range of 0.55-1.38 L/kg/h and that of entacapone is in the range of 0.70 L/kg/h. The elimination-half life is (t<sub>1/2</sub>) is 0.6 - 1.3 hours for levodopa, 2 -3 hours for carbidopa and 0.4 - 0.7 h for entacapone, each given separately.</p><p>Due to short elimination half-lives, no true accumulation of levodopa or entacapone occurs on repeated administration.</p><p>Data from <em>in vitro</em> studies using human liver microsomal preparations indicate that entacapone inhibits cytochrome P450 2C9 (IC50 ~ 4 &micro;M). Entacapone showed little or no inhibition of other types of P450 isoenzymes (CYP1A2, CYP2A6, CYP2D6, CYP2E1, CYP3A and CYP2C19) (see section INTERACTIONS).</p><p>Characteristics in patients</p><p>Elderly</p><p>In elderly patients given levodopa without carbidopa and entacapone, absorption is greater and elimination is slower than in young subjects. However, when combined with carbidopa, the absorption of levodopa is similar in both elderly and the young patients, although the AUC is still 1.5 times greater in the elderly due to decreased DDC activity and lower clearance caused by aging. There are no significant differences in the AUC of carbidopa or entacapone between younger (45&ndash;64 years) and elderly subjects (65&ndash;75 years).</p><p>Gender</p><p>The bioavailability of levodopa is significantly higher in women than in men. In the pharmacokinetic studies with Stalevo<sup> </sup>the bioavailability of levodopa is higher in women than in men, primarily due to the difference in body weight, while there is no gender difference with carbidopa and entacapone.</p><p>Hepatic impairment</p><p>The metabolism of entacapone is slowed in patients with mild to moderate hepatic impairment (Child-Pugh Class A and B) leading to an increased plasma concentration of entacapone both in the absorption and the elimination phases (see sections DOSAGE REGIMEN AND ADMINISTRATION and CONTRAINDICATIONS). No specific studies on the pharmacokinetics of carbidopa and levodopa in patients with hepatic impairment have been reported. However, it is advised that Stalevo<sup> </sup>should be administered with caution in patients with mild or moderate hepatic impairment.</p><p>Renal impairment</p><p>Renal impairment does not affect the pharmacokinetics of entacapone. No specific studies are reported on the pharmacokinetics of levodopa and carbidopa in patients with renal impairment. However, a longer dosing interval of Stalevo may be considered for patients who are receiving dialysis therapy (see section DOSAGE REGIMENAND ADMINISTRATION).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data for levodopa, carbidopa and entacapone tested alone or in combination revealed no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential. In repeated dose toxicity studies with entacapone, anaemia, most probably due to iron chelating properties of entacapone, was observed. Regarding reproduction toxicity of entacapone, decreased foetal weight and a slightly delayed bone development were noticed in rabbits treated at systemic exposure levels in the therapeutic range. Both levodopa and combinations of carbidopa and levodopa have caused visceral and skeletal malformations in rabbits.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet core: croscarmellose sodium, magnesium stearate, maize starch, mannitol, povidone.</p><p>&nbsp;</p><p>Film-coating: glycerol 85%, hypromellose, magnesium stearate, polysorbate 80, red iron oxide (E 172), sucrose, titanium dioxide (E 171), yellow iron oxide (E 172). (Note: yellow iron oxide not used in 75/18.75/200 mg, 125/31.25/200 mg and 200/50/200 mg tablets).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Stalevo must be kept out of the reach and sight of children.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>HDPE bottles with PP-closure.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Marketing Authorization Holder for this Product is Novartis Pharma AG. 
www.Novartis.com


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Approved by Novartis Pharmaceutical Company on May-2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>